Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 202123-01-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 2021Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Tele/Video Conference - One on One meeting with Motilal Oswal Financial ServicesGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report dated January 22, 2021 in respect of utilization of proceeds of IPO for the quarter ended December 31, 2020 issued by M/s. Axis Bank Limited, Monitoring AgencyGland Pharma Q3 net rises 32% to 204 crore
Gland Pharma Limited has posted robust results for the third quarter and nine months ended December 31, 2020 with the company logging a profit of 204Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Board of Directors on recommendation of the ESOP Compensation Committee of the Board of Directors of the Company has allotted 217,850 Equity shares of Rs.1/- each of the Company, fully paid-up, on January 22, 2021 to employees on exercise of their stock options pursuant to Gland Pharma Stock Options Scheme, 2019. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 163,500,673/- comprising of 163,500,673 Equity shares of face value Rs. 1/- each.Gland Pharma Ltd - 543245 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2020
The Board of Directors at its meeting held on January 22, 2021 has inter- alia approved the Unaudited Financial Results of the Company for the Quarter and Nine months ended December 31, 2020Gland Pharma Ltd - 543245 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 037370 Name of the Signatory :- p sampath kumarDesignation :- Company Secretary and Compliance OfficerGland Pharma Ltd - 543245 - Shareholding for the Period Ended December 31, 2020
Gland Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click hereGland Pharma Ltd - 543245 - Earnings Conference Call
Earnings Call for Investors/Analysts to be held on Friday, 22nd January, 2021 at 1830 hours ISTGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Notice of Board Meeting - Advertisement